OTS - LEUKOCARE grants license to US vaccine company PaxVax
2016. September 13. 09:00
Munich, 13 September, 2016 (APA/OTS) - LEUKOCARE AG, Germany, and
PaxVax, Inc., USA, today announced that both partners have entered
into a licensing agreement granting PaxVax access to LEUKOCARE's
proprietary SPS® formulation technology platform for the clinical
development and subsequent commercialization of one of PaxVax's
live viral vaccine products.
The licensing agreement provides to PaxVax exclusive access to
two product-specific pharmaceutical formulations based on
LEUKOCARE's Stabilizing and Protecting Solutions (SPS®) formulation
platform. The undisclosed live adenovirus-based vaccine candidate
will enter clinical trials by early 2017. Under the terms of the
agreement, LEUKOCARE will receive milestone payments and annual
license fees during development and undisclosed royalties on net
sales during commercialization of the vaccine.
"For the entire pre-clinical development phase of the product
LEUKOCARE has been a reliable partner in supporting our efforts to
develop stabilizing formulations for our adenovirus-based vaccine.
We are very pleased that the product will soon enter clinical
trials", said Jonathan Smith, CSO of PaxVax.
Michael Scholl, CEO with LEUKOCARE, said: "This license
agreement with PaxVax demonstrates again our ability and strong
expertise to back up our industry partners in pharmaceutical
formulation development. We are proud to be involved in the
successful product development of PaxVax and to support their
efforts to bring the product into clinic and eventually to market.
About LEUKOCARE
LEUKOCARE provides a next-generation formulation platform for
the protection of proteins like biopharmaceuticals to allow the
development of better products. The proprietary SPS® technologies
are provided to development projects of partners in the
pharmaceutical and medical device industry. LEUKOCARE's SPS®
technologies improve stability and quality of biologics like
antibodies, vaccines etc. in dry and liquid formulation. SPS® also
protect proteins in biologically functionalized combination devices.
www.LEUKOCARE.com
About PaxVax
PaxVax develops, manufactures and commercializes innovative
specialty vaccines against infectious diseases for traditionally
overlooked markets such as travel. PaxVax has licensed vaccines for
typhoid fever (Vivotif) and cholera (Vaxchora), and vaccines at
various stages of research and clinical development including for
adenovirus, anthrax, hepatitis A, HIV, and zika. As part of its
social mission, PaxVax is also working to make its vaccines
available to broader populations most affected by these diseases.
PaxVax is headquartered in Redwood City, California and maintains
research and development and Good Manufacturing Practice (GMP)
facilities in San Diego, California and Bern, Switzerland and other
operations in Bermuda and Europe. More information is available at
www.PaxVax.com.
Contact:
Michael Scholl
Michael.scholl@leukocare.com
+49(0)8978016650
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók a
forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.